
Clinical TrialNov 16, 2026, 08:36 AM
Clearmind Medicine Completes Enrollment for CMND-100 Phase I/IIa Trial Part C
AI Summary
Clearmind Medicine Inc. has achieved a significant clinical milestone by completing patient enrollment for Part C of its Phase I/IIa clinical trial evaluating CMND-100. This part of the trial is a randomized, double-blind, placebo-controlled study focused on assessing the safety, tolerability, and pharmacokinetic profile of the drug candidate. The company anticipates that the data generated will further support the advancement of CMND-100, a non-hallucinogenic psychedelic-derived neuroplastogen aimed at treating neuropsychiatric, metabolic, and addiction disorders.
Key Highlights
- Clearmind Medicine Inc. announced full patient enrollment for Part C of its CMND-100 Phase I/IIa clinical trial.
- Part C is a randomized, double-blind, placebo-controlled multiple-dose study assessing safety, tolerability, and pharmacokinetics of CMND-100.
- The trial is being conducted at leading research sites including Johns Hopkins, Yale, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center.
- CEO Dr. Adi Zuloff-Shani stated the enrollment completion demonstrates continued momentum for the CMND-100 program.
- Data from Part C is expected to enhance understanding of CMND-100's profile to support future development.
Price Impact
More from CMND